New products drive Roche 1st-qtr sales growth

22 April 2020

Volatility in some markets due to the COVID-19 pandemic had limited impact on business performance in the first quarter of 2020, said Swiss pharma giant Roche (ROG: SIX), which this morning reported group sales of 15.14 billion Swiss francs ($15,67 billion), showing growth of 2% (7% at constant exchange rates).

The revenues figure beat consensus expectations of 14.65 billion francs compiled by FactSet.

Within this, Pharmaceutical Division sales came in at 12.26 billion francs, up 3% (+7% at CER) while the Diagnostics Division revenues came in at 2.88 billion francs, down1% (+5% at CER).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK